Main Publications



Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
Kim Fox, Ian Ford, P. Gabriel Steg, Michal Tendera, Michele Robertson, Roberto Ferrari on behalf of the BEAUTIFUL investigators


Ivabradine and cardiovascular events in stable coronary artery disease and left ventricular systolic dysfunction: a randomised, double-blind, placebo-controlled trial
K Fox, I Ford, P G Steg, M Tendera, R Ferrari, on behalf of the BEAUTIFUL Study Group


Heart rate as a prognostic risk factor in patients with coronary disease and left ventricular dysfunction
K Fox, I Ford, P G Steg, M Tendera, M Robertson, R Ferrari - On behalf of the BEAUTIFUL investigators


The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction Baseline Characteristics of the Study Population
Cardiology. 2008;110:271282. The BEAUTIFUL Study Group.


Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study
Am Heart J. 2006 Nov;152(5):860-6.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee.